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Recently we demonstrated that the decavanadate (V10) ion is a stronger Ca
2+-ATPase inhibitor than other
oxometalates, such as the isoelectronic and isostructural decaniobate ion, and the tungstate and molybdate
monomer ions, and that it binds to this protein with a 1 : 1 stoichiometry. The V10 interaction is not
affected by any of the protein conformations that occur during the process of calcium translocation
(i.e. E1, E1P, E2 and E2P) (Fraqueza et al., J. Inorg. Biochem., 2012). In the present study, we further
explore this subject, and we can now show that the decaniobate ion, [Nb10 = Nb10O28]
6−, is a useful tool
in deducing the interaction and the non-competitive Ca2+-ATPase inhibition by the decavanadate ion
[V10 = V10O28]
6−. Moreover, decavanadate and vanadate induce protein cysteine oxidation whereas no
effects were detected for the decaniobate, tungstate or molybdate ions. The presence of the antioxidant
quercetin prevents cysteine oxidation, but not ATPase inhibition, by vanadate or decavanadate. Deﬁnitive
V(IV) EPR spectra were observed for decavanadate in the presence of sarcoplasmic reticulum Ca2+-
ATPase, indicating a vanadate reduction at some stage of the protein interaction. Raman spectroscopy
clearly shows that the protein conformation changes that are induced by V10, Nb10 and vanadate are
different from the ones induced by molybdate and tungstate monomer ions. Here, Mo and W cause
changes similar to those by phosphate, yielding changes similar to the E1P protein conformation. The
putative reduction of vanadium(V) to vanadium(IV) and the non-competitive binding of the V10 and Nb10
decametalates may explain the differences in the Raman spectra compared to those seen in the presence of
molybdate or tungstate. Putting it all together, we suggest that the ability of V10 to inhibit the Ca
2+-
ATPase may be at least in part due to the process of vanadate reduction and associated protein cysteine
oxidation. These results contribute to the understanding and application of these families of mono- and
polyoxometalates as effective modulators of many biological processes, particularly those associated with
calcium homeostasis.
1. Introduction
Previous studies have shown that sarcoplasmic reticulum (SR)
Ca2+-ATPase activity is very sensitive to the presence of several
vanadium complexes such as vanadium–citrate complexes and
bis(maltolato)oxovanadium(IV) (BMOV).1,2 It has been
suggested that different vanadium coordination complexes can
inhibit Ca2+-ATPase through speciﬁc protein–substrate inter-
actions while the oligomeric, uncomplexed oxovanadates do not
interact through the same mechanism. Moreover, the different
oligovanadates such as [VO4]
3− (V1), [V4O12]
4− (V4), or
[V10O28]
6− (V10) may have different mechanisms and effects on
the calcium ATPase activity. In particular, V10 is the only
identiﬁed polyoxovanadate that inhibits calcium accumulation
by the Ca2+-ATPase when coupled to ATP hydrolysis.3
In addition, V10 appears to be the most potent oxometalate Ca
2+-
ATPase inhibitor out of all the vanadium ions and complexes so
far analysed, exhibiting an IC50 value of 15 μM.
1–4 Recently,
other transition-metal ion clusters such as niobates, tungstates
and molybdates were evaluated in the inhibition of SR calcium
ATPase and were found to be less efﬁcient as inhibitors.4 These
ﬁndings were further explored, and the effects of ﬁve transition
metal species, viz. decavanadate (V10), decaniobate (Nb10O28
6−,
Nb10), vanadate (V1), tungstate (WO4
3−, W1) and molybdate
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(MoO4
3−, Mo1) ions, on the structure and activity of SR calcium
ATPase were evaluated and described in the present paper.
V10 and Nb10 are isostructural and isovalent, but where
vanadium is redox active and labile in solution, niobium is kine-
tically inert and redox stable, making Nb10 an excellent tool to
explore the type of inhibition that the V10 analogue undergoes
with the calcium pump. The SR calcium pump has proven to be
an excellent model for studying the effects of oxovanadates and
vanadium complexes on Ca2+ homeostasis, and by extension on
several signalling processes in muscle and non-muscle cells.1–4
Calcium homeostasis is also known to be involved in cell death
processes such as necrosis and apoptosis. Finally, ion pumps are
known as potential drug targets in medicine and science.5
Decavanadate is known to modulate the activity of many pro-
teins such as phosphatases,6 myosin,7,8 and calcium pump
ATPase1–4,9,10 and to interact with proteins such as actin11–15
among others.16,17 Moreover, as a well-established inhibitor of
tyrosine kinases and phosphatases, vanadium is suggested to be
involved in the biochemical processes of several diseases, with
potential uses in anticancer18–20 and anti-diabetic therapies.21
For instance, in rat adipocytes, the V10 ion has been suggested to
be a more potent insulin mimetic agent than several mononuclear
vanadium coordination complexes, although the precise mecha-
nism of action is still unclear.22 Perhaps the most notable effect
of V10 described so far relates to the induction of mitochondrial
membrane depolarization and the inhibition of oxygen consump-
tion at nanomolar concentrations, which leads to cell
necrosis.23,24
While the literature on the biological effects of mono- and
polyoxometalates has been rapidly increasing over the most
recent decade, the biochemical mechanisms underpinning
the effects of these oxometalates are still only poorly under-
stood. This is clearly a rapidly growing ﬁeld, owing to the
increasing interest in the use of bioavailable metal complexes
in biochemistry, biology, biotechnology, pharmacology and
medicine.
2. Materials and methods
All reagents were of biochemical analysis grade and were sup-
plied by BDH, Merck, and Sigma. Anhydrous ammonium meta-
vanadate, sodium tungstate and sodium molybdate salts were
purchased from Riedel-de Haën. Tetramethylammonium decan-
iobate, [N(CH3)4]6[Nb10O28]·6H2O, was synthesised according
to published procedures.25,26 ATP (vanadium free) was supplied
by Sigma.
2.1. Preparation of metal solutions
Decavanadate stock solution was obtained by adjusting the pH
of an ammonium metavanadate solution (50 mM, pH 6.7) to 4.0,
according to literature methods,3,16,24 and the formation of the
decavanadate (V10) ion is readily observed by the characteristic
orange colour of the solution.16 The kinetics of decomposition
of V10 is determined by following the absorbance at λ 400 nm of
the reaction medium at 25 °C, as described elsewhere.16,23,27 V10
decay follows a ﬁrst-order rate law, with a half-life of more than
12 h (measured with 0.1 mM decameric vanadate species, 1 mM
total vanadate), in agreement with previous work.27 At the V10
concentrations and time-scales used in the enzymatic studies per-
formed in the present work, the vanadium solution contains
almost exclusively the decameric species. On the other hand,
vanadate solutions up to 1 mM contain mostly monomeric,
dimeric and tetrameric vanadate species, as determined using
NMR spectroscopy.3,27 Stock solutions of sodium tungstate and
sodium molybdate were prepared in milliQ water. A solution of
decaniobate was prepared in water as a stock concentration of
10 mM, with a self-buffered pH of 6.0. Decaniobate solutions
are stable under these conditions, as shown elsewhere.25,26
Under the experimental conditions used in this study, the
addition of the metals to the reaction medium, within the concen-
tration ranges used in the study, did not change the pH of the
medium.
2.2 Preparation of sarcoplasmic reticulum vesicles
Isolated sarcoplasmic reticulum vesicles (SRV), prepared
from skeletal rabbit muscles, were suspended in 0.1 M KCl,
10 mM HEPES (pH 7.0), diluted 1 : 1 with 2.0 M sucrose and
frozen in liquid nitrogen prior to storage at −80 °C, as described
elsewhere.3,11 The protein concentration was determined spectro-
photometrically at 595 nm, by the Bradford method, using
bovine serum albumin as a standard and in the presence of
0.125% of sodium dodecyl sulphate (SDS). The percentage of
each protein present in the SR-vesicle preparations was deter-
mined through densitometry analysis of SDS-polyacrylamide
gel electrophoresis (7.5% acrylamide). The SR Ca2+-ATPase
analysed by SDS polyacrylamide gel electrophoresis comprised
at least 70% of the total protein in the SR-vesicles.
The SERCA-1 (sarcoplasmic, or endoplasmic reticulum
Ca2+-ATPase-1) was the predominant isoform in our SR
preparations.28
2.3 ATP hydrolysis by a calcium pump
Steady-state assays of the sarcoplasmic reticulum Ca2+-ATPase
were measured spectrophotometrically at 25 °C using the
coupled enzyme pyruvate kinase/lactate dehydrogenase assay, as
described elsewhere,2,28 under the following conditions: 25 mM
HEPES (pH 7.0), 100 mM KCl, 5 mM MgCl2, 50 μM CaCl2,
2.5 mM ATP, 0.42 mM phosphoenolpyruvate, 0.25 mM NADH,
18 IU lactate dehydrogenase and 7.5 IU pyruvate kinase, with or
without vanadate, decavanadate, decaniobate, tungstate or moly-
bdate, in the absence or in the presence of the following anti-
oxidants, wherever stated: glutathione (GSH) (1 mM), quercetin
(10 μM) or kaempferol (10 μM). The experiments were initiated
by the addition of 10 μg mL−1 calcium ATPase, in the presence
or absence of 4% (w/w) of calcium ionophore A23187, and fol-
lowed for 5 min. Metal solutions were added to the medium
immediately prior to protein addition. The absorbance of the
metal solutions did not interfere with the determination of the
reaction rates at the chosen wavelength of 340 nm. Furthermore,
within the concentration range studied, the oxometalates did not
affect the coupled enzyme method used in the assays, as
observed upon addition of 40 μM ADP.
Dalton Trans. This journal is © The Royal Society of Chemistry 2012
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2.4 Measurements of reduced cysteine residues
The titration of accessible reduced cysteine residues in sarcoplas-
mic reticulum Ca2+-ATPase was done in the absence of denaturants
and was performed with DTNB (5,5′-dithiobis-(2-nitrobenzoic
acid)), as indicated in previous work,13,23,24,29 using an extinc-
tion coefﬁcient at 412 nm of 14.150 M−1 cm−1 for the colored
product TNB (2-nitro-5-thiobenzoate). The assays were carried
out in HEPES (pH 7.0), 100 mM KCl, 5 mM MgCl2 and
55 mM sodium-phosphate buffer (pH 7.2), following 5 min of
incubation of 0.2 mL SR (1 mg mL−1) with vanadate, decavana-
date, decaniobate, tungstate or molybdate, in the absence or in
the presence of the following antioxidants, wherever stated:
quercetin (10 or 100 μM) or kaempferol (10 or 100 μM).
2.5 Electron paramagnetic resonance spectroscopy
X-band (9.65 GHz) EPR spectra were acquired on a Bruker
EMX 6/1 spectrometer equipped with a Bruker ER4116DM
rectangular cavity. The samples were cooled to 77 K with an
Oxford Instruments ESR900 continuous-ﬂow cryostat (with
liquid helium), ﬁtted with a temperature controller. The acqui-
sition conditions involved a ﬁeld modulation frequency of
100 kHz, a 10 G modulation amplitude, a microwave power
of 635 μW, a time constant of 163.840 ms, with a sweep time of
335.544 s; the spectra were acquired by sweeping the magnetic
ﬁeld between 2400 and 4400 G. The decavanadate reduction and
subsequent vanadyl(IV) formation were evaluated using the same
samples prepared for the NMR measurements (vide infra).
2.6 NMR measurements
51V NMR spectroscopy measurements were performed on a
Bruker AM-400 MHz (9.4 T; 51V 105.2 MHz) spectrometer
equipped with a 5 mm multinuclear inverse probe. Spectra were
acquired at 22 °C using 0.5 mL of samples containing 10% D2O
using a calibrated π/2 pulse. 12 000–25 000 scans were acquired
with recycling delays of 10 ms, acquisition times of 86 ms at a
spectral width of 45.454 kHz, as described elsewhere.3
The 51V-NMR chemical shifts are reported relative to an exter-
nal reference of VOCl3, as described in previous work.
1–4,27
NMR spectra of decavanadate (5 mM total vanadium) in a reac-
tion medium containing 25 mM HEPES (pH 7.0), 100 mM KCl,
5 mM MgCl2 and 50 μM CaCl2 were obtained in the absence or
in the presence of sarcoplasmic reticulum vesicles (5 mg mL−1
total protein) and 2.5 mM ATP. Similarly, NMR spectra were
obtained in the presence of 1 mM of decaniobate (Nb10) in the
absence or presence of 2.5 mM ATP. The reported 51V-NMR line
widths of the free and bound vanadate resonances represent the
full widths at half-maximum (Δν1/2) height after subtraction of
the 20 Hz used for exponential line broadening during proces-
sing. The concentration of each vanadate species Vx was calcu-
lated from the fractions of the total integrated areas using the
following equation: [Vx] = (Ax/At) × ([Vt]/n), where Ax corres-
ponds to the area measured for the vanadate species X with
n aggregation number (number of vanadium atoms), At the sum
of measured areas, and [Vt] the total vanadate concentration, as
described elsewhere.3,23,27
2.7 Atomic absorption analysis
Vanadium analysis was performed by atomic absorption spectro-
scopy (AAS), as described elsewhere.4 Brieﬂy, all the protein
samples in a reaction medium similar to the above NMR studies,
in the absence and in the presence of decavanadate, were centri-
fuged at 17 000 rpm (40 000g), during 60 min at 4 °C. The
supernatant solutions over the centrifuged samples were then
analysed using a GBC Avanta atomic absorption spectrometer.4
The vanadium lamp was operated at 318.2 nm, with a slit width
of 0.2 nm, and the instrument was calibrated against a series of
solutions containing 50, 100, 150 and 200 ppb of vanadium.
Calibration standards were obtained by successive dilutions of a
Merck standard solution of vanadium 1002 ± 2 mg L−1. The
detection and quantiﬁcation limits of the instrument for these
analysis conditions, determined according to ISO 8466-1, were
5 ± 1 μg L−1 of vanadium. The method was validated using a
certiﬁed reference material (TORT-1’s vanadium content 1.4 ±
0.3 mg kg−1) purchased from the National Research Council of
Canada.
2.8 Raman spectroscopy
The Raman spectra were obtained at room temperature, in a
triple monochromator Jobin-Yvon T64000 Raman system (focal
distance 0.640 m, aperture f/7.5) equipped with holographic
gratings of 1800 grooves per mm. The premonochromator stage
was used in the subtractive mode. The detection system was a
liquid nitrogen cooled non-intensiﬁed 1024 × 256 pixel (1′′)
Charge Coupled Device (CCD) chip. The 514.5 nm line of an
Ar+ laser (Coherent, model Innova 300-05) was used as the exci-
tation radiation, providing ca. 50 mW at the sample position.
A 90° geometry between the incident radiation and the collecting
system was employed. The entrance slit was set to 200 μm, and
the slit between the premonochromator and the spectrograph was
400 μm.
Samples were sealed in Kimax glass capillary tubes of
0.8 mm inner diameter. Under the above mentioned conditions,
the error in wavenumbers was estimated to be within 1 cm−1.
2.9 Statistical analyses
All parameters studied are present as averages and standard devi-
ations of measurements taken from triplicate measurements from
three SR preparations. Student’s t-test pairwise sets were used.
3. Results and discussion
Oxometalates, in particular decavanadate (V10), can act as dra-
matic inhibitors (IC50 = 15 μM) of the hydrolytic activity of
sarcoplasmic reticulum Ca2+-ATPase,1 a transmembrane protein
involved in calcium translocation and responsible for muscle
relaxation.30 Vanadium is used as a functional and structural tool
in many biological studies involving ion pumps and other types
of enzymes, since it is well established that monomeric vanadate(V)
can mimic transition states involved in phosphoryl-transfer reac-
tions, once the chemical structure is very similar to phosphate.31
However, the physiological role of vanadium and the mode of
This journal is © The Royal Society of Chemistry 2012 Dalton Trans.
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action in the hydrolytic activity of sarcoplasmic reticulum Ca2+-
ATPase, an important process in Ca2+ homeostasis, are not
understood. In the present study, we further investigate the
effects of niobate, vanadate, molybdate and tungstate oxometa-
lates on the structure and function of the sarcoplasmic reticulum
Ca2+-ATPase, in order to reveal new insight into metal–protein
interaction processes and the effects on calcium homeostasis, by
combining NMR, atomic absorption, EPR and Raman spectro-
scopies with enzyme kinetic studies.
3.1. NMR and enzymatic studies
Early work using 51V-NMR to explore the interaction between
oxovanadates and proteins focussed on SR Ca2+-ATPase,9 but
since then the method has been applied to a variety of biomole-
cules including the muscle proteins myosin and actin, among
others.3,12,16,17,32–35 In general, it was found that the interaction
of the protein with a speciﬁc vanadate(V) species induced
changes in the intensity and shape of the correspondent vanadate
NMR signals. In some studies, these changes were not observed
if the interaction was prevented by the presence of the protein’s
natural ligands,3,12,33 offering an insight into the preferred
modes of interaction of vanadium with these substrates. In the
present study, broadening of the observed V10 NMR signal
showed that V10 interacts with the calcium pump, the interaction
being stronger in the presence of ATP, the natural ligand of SR
ATPase, once the Δν1/2 increased from 3 to 4 (Fig. 1A, Table 1).
V10 typically shows a 1 : 2 : 2 ratio of 3 peaks, namely 10A, 10B
and 10C, in its 51V NMR spectrum (Fig. 1A).3,12,33,34 Similar
line broadening has been described in cases where oligomeric
oxovanadates were associating with a protein3,11,12,16,33 or with a
lipid structure.34 Moreover, it was observed that Nb10 prevents
the interaction of the isostructural V10 with the protein, as evi-
denced by a sharpening of the decavanadate signal once the
V10A line broadening decreases from 3 to 2.5 (Fig. 1B, Table 1),
suggesting that they compete for the same binding site, a site
which is different from the ATP binding site. C2 and C1 are
NMR signals ascribed to vanadate–sucrose complexes, described
elsewhere,3 once the SR Ca2+-ATPase samples contain sucrose.
Although V10 has been shown to be an enzyme modu-
lator,4,6,16,17,35 little is known about the type of inhibition
it engages in.3,4,6 In addition, the rich solution chemistry of
vanadium as evidenced by its propensity to form a wide range of
species in solution coupled with the thermodynamic lability
of the V10 ion speciﬁcally opens up the possibility that the
species of vanadium present in solution under the experimental
conditions may not always be the one intended – or even sus-
pected. This is particularly true for experiments that require long
incubation times, complex solvent compositions or elevated
temperatures, which increases the rates of V10 decompo-
sition.16,17,23,24,27,35 Because of this it is imperative that the
vanadium species present in solution are carefully characterised
before attributing a particular biological effect or a biochemical
mechanism to a speciﬁc ion species.3,16,17,23,24,27,35
In the present study, the inhibition of the ATPase activity by
V10 was found to be competitive for lower concentrations
(10 μM) and non-competitive for higher concentrations (50 μM)
(Fig. 2A) of V10. Previously, it was shown that the isostructural
Nb10 inhibits non-competitively at both concentrations.
4
However, while Nb10 is stable and relatively inert under these
conditions, V10 is not and is highly reactive. The formation and
presence of monomeric vanadate might be responsible for the
processes of competitive inhibition, seen at lower V10 concen-
trations (10 μM). Therefore, it is suggested that while V10, like
Nb10,
4 interacts with calcium ATPase non-competitively, the for-
mation of monomeric vanadium(V) species is responsible for
competitive interaction. This is similar to what is seen for tung-
state (Fig. 2B). Tungstate (W1) has a lower SR Ca
2+-ATPase
inhibition capacity than decavanadate4 (IC50 = 400 μM for W1
and IC50 = 15 μM for V10), although higher than described for
Na+-K+-ATPase inhibition (W1 IC50 = 1.5 mM).
36 For this
enzyme, other polyoxotungstates (W12) present a higher capacity
of inhibition, with IC50 less than 15 μM, the value found above
for V10.
36 It thus seems that the decavanadate–calcium pump
interaction is favoured in the presence of ATP but is prevented
by the iso-structural and iso-electronic decaniobate ion and V10
non-competitively inhibits the enzyme activity vis-à-vis ATP.
Other studies, however, have found that the interaction of V10
with the calcium pump is competitive, it binds to two sites,9,37
and have suggested that V10 will bind to the calcium pump at the
vanadate-binding site, or to the nucleotide binding site.9,37,38
This has led to the suggestion that the V10-binding site is the
same as the ATP binding site or at least close to it, since it has
been observed that a covalent inhibitor that binds speciﬁcally to
Lys-515 within the ATP binding site also prevents V10 from
binding to the ATPase.38
Structural studies based on V10-induced crystallization of
the calcium pump complex have indicated that the V10 binding
site in the E2 conformation of the SR ATPase is located in the
intersection of the three cytoplasmic protein domains that
includes the nucleotide, the phosphorylation and the β-strand
domains.10 It should be noticed that some ATPase enzymes
include many membrane enzymes such as the E1E2-ATPases.
Although many details are known with regard to the biochemical
mechanisms of these ATPases, inhibitory studies assume that
vanadate acts as a phosphate analogue and presumably inhibits
the enzymes as a transition-state analogue for the phosphoryl
group transfer. However, E1–E2 ATPases are not truly an
ATPase but a phosphohydrolase, once what is hydrolyzed is the
phosphate that is covalently bound to the enzyme, rather than
ATP. Further studies are needed to clarify the interaction and the
effects of V10 on the structure and function of the calcium pump,
once it seems that it does not behave like vanadate, a phosphate
analogue.
Fig. 1 105.2 MHz 51V-NMR spectra, at room temperature, of 0.5 mM
decavanadate (5 mM total vanadate) in 25 mM HEPES (pH 7.0),
100 mM KCl, 5 mM MgCl2, 50 μM CaCl2 with (A) SR calcium
ATPase, plus 0.25 mM ATP or niobate, and (B) upon niobate addition.
Dalton Trans. This journal is © The Royal Society of Chemistry 2012
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3.2. Atomic absorption and EPR spectroscopy with cysteine
oxidation studies
Using atomic-absorption spectroscopy (AAS) V10 has been
shown to bind to an equal extent to all protein conformations
that occur during the process of calcium translocation, viz. E1,
E1P, E2 and E2P.4 Thus the amount of V10 that was found to
bind to each conformer of the enzyme was the same, and was
independent of the medium conditions that favoured each protein
conformation. A likely possibility is that the V10 binding is
always available independently of the calcium translocation-
dependent conformational changes. This is in stark contrast with
what has been observed for monomeric vanadate, as vanadium
binding to the protein is clearly prevented in the E1 confor-
mation, but is favourable when the protein is in the E2
conformation.4,10
In this study we observe that Nb10 prevents the interaction of
V10 with the calcium pump once the amount of vanadium bound
to the protein decreases by about 50%, whereas no effects were
observed for heparin, a molecule known to interact with nucleo-
tide binding sites (Fig. 3). Using NMR it was conﬁrmed that the
isostructural Nb10 prevents the V10 from interacting with the
protein. The fact that V10 inhibition would be non-competitive,
as suggested above, and that the interaction with the calcium
pump is independent of the protein conformation may point to a
speciﬁc mode of interaction with the calcium pump that is
clearly different from the one described for vanadate alone. This
observation, in agreement with previous functional studies exe-
cuted at conditions very close to physiological ones, means that
V10 is the only vanadate species able to prevent calcium trans-
location coupled to ATP hydrolysis, whereas no effect is found
for a normal vanadate solution, not containing V10, up to con-
centrations of 2 mM.3
On the other hand, more recently the IC50 value of calcium
ATPase inhibition for Nb10 (IC50 = 35 μM) was found to be
more than twice that of V10 (IC50 = 15 μM).
4 This shows that
V10 may have a different mode of protein interaction. Mono-
meric vanadate (V1), a product of V10 decomposition in the
medium, may also contribute to the inhibition effects. However,
as indicated by AAS, monomeric vanadate interaction should
not be favoured under conditions where calcium is present and
the E1 conformation is dominant. In addition, the inhibition of
the calcium ATPase by monomeric vanadate is less effective.
There is evidence that vanadate can form a complex with ATP
itself, as is expressed through broadening of the monomeric
vanadate signal in the presence of ATP,3 and a similar type of
complex formation has been suggested with myosin.11,12 It is
also possible that the V10 mediated inhibition of calcium ATPase
Table 1 Chemical shifts (δ), line widths (Δν1/2), and broadening factor of the line widths (f) of monomeric (V1), dimeric (V2), tetrameric (V4) and
decameric (V10) forms of vanadate present in 5 mM nominal decavanadate solution (0.5 mM V10) under different experimental conditions
Decavanadate (0.5 mM)
V10C V10B V10A V1 V2 V4 C2 C1
Medium
δ/ppm −421.0 −495.0 −512.0 −558.0 −571.0 −575.0 −537.0 −551.0
Δν1/2/Hz 1394.0 996.0 398.0 199.0 398.0 199.0
Area 2.5 6.4 10.4 4.3 1.0 5.6
[+SR Ca2+-ATPase (5 mg mL−1)]
δ/ppm −421.0 −495.0 −512.0 −558.0 −571.0 −575.0 −537.0 −551.0
Δν1/2/Hz 2788.0 2390.0 1195.0 199.0 996.0 1095.0
f (2.0) (2.4) (3.0) (1.0)
Area 3.6 5.4 8.5 1.2 1.0 2.8
[+SR Ca2+-ATPase (5 mg mL−1) + ATP (2.5 mM)]
δ/ppm −421.0 −495.0 −512.0 −558.0 −571.0 −575.0 −537.0 −551.0
Δν1/2/Hz 3386.0 2589.0 1593.0 1195.0 1195.0
f (2.4) (2.6) (4.0)
Area 2.9 5.4 6.9 0.9 2.0
[+SR Ca2+-ATPase (5 mg mL−1) + Nb10 (1 mM)]
δ/ppm −421.0 −495.0 −512.0 −558.0 −571.0 −575.0 −537.0 −551.0
Δν1/2/Hz 2190.0 1991.0 996.0 199.0 996.0 1095.0
f (1.6) (2.0) (2.5) (1.0)
Area 2.6 5.8 9.6 0.9 0.8 2.0
[+SR Ca2+-ATPase (5 mg mL−1) + Nb10 (0.5 mM)]
δ/ppm −421.0 −495.0 −512.0 −558.0 −571.0 −575.0 −537.0 −551.0
Δν1/2/Hz 2788.0 2190.0 996.0 199.0 1195.0 1195.0
f (2.0) (2.2) (2.5) (1.0)
Area 3.3 5.8 9.5 0.6 0.8 2.0
[+SR Ca2+-ATPase (5 mg mL−1) + ATP (2.5 mM) + Nb10 (1 mM)]
δ/ppm −421.0 −495.0 −512.0 −558.0 −571.0 −575.0 −537.0 −551.0
Δν1/2/Hz 2788.0 1991.0 1195.0 1195.0 1195.0
f (2.0) (2.0) (3.0)
Area 2.9 4.7 8.4 0.5 1.4
This journal is © The Royal Society of Chemistry 2012 Dalton Trans.
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involves oxidation of the cysteine units in the protein, which
would certainly affect the activity of the enzyme.39 This would
also lead to the reduction of vanadate(V) to vanadyl(IV), which is
an EPR active species. Such a signal was indeed found, and only
for either vanadate or V10 incubation with calcium ATPase
(Fig. 4), but not in the absence of the calcium ATPase. This is
strong evidence that cysteine units in the protein are oxidized in
the presence of vanadium(V), as has previously been reported in
similar experiments with myosin or with actin.12,13,40
Actin was described as a potential target for decavanadate,
being suggested to reduce the metal and to bind with vanadyl
with a 1.1 stoichiometry.11–15 This explains the difference in the
inhibition caused by Nb10 vs. V10 in spite of them being iso-
structural and isovalent: while the standard reduction potential of
VO2
+ to VO2+ is +1.0 V, under acidic conditions niobium(V)
isn’t known to be easily reduced.25,26 This difference in redox
activity means that while vanadate can reduce cysteine (E0 ∼
−0.15 V, values referred are vs. the standard hydrogen electrode
and reported at pH 7), niobate won’t. In fact, only the vanadate
and V10 species induced protein cysteine oxidation, whereas no
evidence of oxidation was detected for the other Nb, W and Mo
oxometalates (Fig. 5). Furthermore, adding antioxidants such as
quercetin or kaempferol (100 μM) partially reversed the cysteine
oxidation induced by vanadate (Fig. 5). With other antioxidants,
such as GSH (1 mM), it was not possible to evaluate the
effect, due to interferences in the method, because the com-
pounds absorbed at the wavelength of the measurement or
it formed complexes with the antioxidants. For the same
reasons the antioxidant reversion of cysteine oxidation induced
by V10 could not be determined. Apparently, V10 is reacting with
the antioxidant. All the data, however, point towards the oxi-
dation of cysteine being a key part of the inhibitory mechanism
of V10 towards calcium ATPase. On the other hand, it means
that vanadate can be reduced by thiols not only in biological
conditions,41 but particularly upon interaction with speciﬁc
proteins such as actin13 and also with the calcium pump, as
described above.
Fig. 2 (A) Lineweaver–Burk plot of the inhibition of the sarcoplasmic
reticulum calcium pump with V10. Concentrations in vanadium are
referred as decavanadate concentrations. ATPase activity was measured
as indicated in the Materials and methods section. Data are plotted as
means ± SD. The results shown are the average of triplicate experiments.
(B) Lineweaver–Burk plot of the inhibition of the sarcoplasmic reticu-
lum calcium pump with W. Concentrations in tungstenium are referred
as tungstate concentrations. The ATPase activity was measured as indi-
cated in the Materials and methods section. Data are plotted as means ±
SD. The results shown are the average of triplicate experiments.
Fig. 3 Vanadium analysis performed by atomic absorption spec-
troscopy (AAS). V10 samples containing 1 μM vanadate species, upon
addition of an equal concentration of sarcoplasmic reticulum (SR)
calcium ATPase (1 μM), in the presence of heparin or decaniobate, in
the medium containing 25 mM HEPES (pH 7.0), 100 mM KCl, 5 mM
MgCl2, 50 μM CaCl2 and 0.25 mM ATP, were centrifuged and the super-
natant analyzed by AAS, as described in the Materials and methods
section. The concentrations of vanadium, for V10 solutions, were plotted
against the several medium conditions. Data are plotted as means ± SD.
The results shown are the average of triplicate experiments.
Fig. 4 X-band EPR spectra of 0.5 mM decavanadate (5 mM total
vanadate) in 25 mM HEPES (pH 7.0), 100 mM KCl, 5 mM MgCl2,
50 μM CaCl2 with SR calcium ATPase, in the absence (A) and in
the presence of 0.25 mM ATP (B). The spectra were acquired as
described under Materials and methods. Upon protein addition the
oxidovanadium(IV) typical signals are elicited.
Dalton Trans. This journal is © The Royal Society of Chemistry 2012
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It has been suggested that only one or two cysteine (Cys)
residues of the SR Ca2+-ATPase are critically important for the
function of the enzyme.39 Modiﬁcation of Cys349, located near
the phosphorylation binding site, causes modulation of the SR
Ca2+-ATPase activity by peroxynitrite.42 In this case the oxi-
dation could be reverted by GSH, but for high concentrations of
oxidizing agents the content of the SH group decreases and the
effect cannot be reverted, i.e. the oxidation is irreversible.39
In fact, Ca2+-ATPase inhibitory effects promoted by reactive
oxygen and nitrogen species,39,42 as well as the antitumor drug
3-bromopyruvate,43 all appear to involve protein cysteine oxi-
dation. To verify that glutathione (GSH) could reverse the
decrease in calcium ATPase activity induced by the oxometa-
lates, GSH was added to the medium just prior to oxometalate
addition. Although cysteine oxidation was still observed for the
two vanadate solutions, GSH could not prevent or revert the
inhibition and similar IC50 values were obtained with or without
GSH (Fig. 6A), for all the oxometalates. Quercetin and kaemp-
ferol, antioxidants present in tea, grapes and apples, were also
ineffective, suggesting that the inhibitory effects are not a conse-
quence of cysteine oxidation, or that the speciﬁc cysteine oxi-
dation does not contribute signiﬁcantly for the modulation of the
ATPase activity (Fig. 6B).
Therefore it is suggested that V10 induces oxidation of
cysteine but that only partially modulates the ATPase activity.
Speculating, this cysteine unit is likely located near the nucleo-
tide binding site, such as Cys675 or Cys674, not particularly
involved in the modulation of the enzyme activity. Decavanadate
binding to the calcium ATPase may involve all the three cyto-
plasmic domains, but near the phosphorylation binding site, as
described elsewhere.10,44 Decavanadate ﬁts in the protein like a
ball in a vise preventing the vise from closing.44 This binding
locus would explain the inhibitory effect V10 has on SR Ca
2+-
ATPase activity and on calcium translocation, as described
previously.3,4,16,17,35
3.3. Raman spectroscopy studies
In order to better understand the structural changes induced by
the oxometalates on the calcium ATPase, the process was studied
using Raman spectroscopy to explore the conformations of
calcium ATPase which dominate in the presence of oxometa-
lates. Raman spectroscopy is highly sensitive towards small
structural changes in protein structure and has been a versatile
tool in investigating protein structure modiﬁcation caused by
metal interactions.45,46
As is the case with infrared spectroscopy, the Raman spectrum
contains several diagnostic regions which correspond to speciﬁc
vibrational modes belonging to common structural motifs seen
in proteins.45–48,50–52 These include a band at ca. 855 cm−1
which belongs to tyrosine residues, and a band at ca. 930 cm−1
indicative of α-helices46–48,50 (Fig. 7A). Raman spectroscopy
has been used to follow peptide tyrosine phosphorylation using
the two bands between 820 and 855 cm−1 48–50 that are observed
in the absence of phosphorylation.
Several bands that are sensitive to the average conformation of
the protein can be identiﬁed in the Raman spectrum, and these
can be used to evaluate the protein conformational changes
Fig. 5 Calcium ATPase cysteine (Cys) redox state, after oxometalates
exposition. The accessible thiol groups, in the absence of denaturants,
were measured as indicated in the Materials and methods section. Data
are plotted as means ± SD. The results shown are the average of tripli-
cate experiments. Titration of cysteines was carried out in HEPES (pH
7.0), 100 mM KCl, 5 mM MgCl2 and 55 mM sodium phosphate buffer
(pH 7.2), after 5 min of incubation of 0.2 mL SR (1 mg mL−1) with
vanadate (1 mM), decavanadate (0.3 mM), decaniobate (0.035 mM),
tungstate (8 mM) or molybdate (45 mM), in the absence or in the pres-
ence of the following antioxidants, wherever stated: GSH (1 mM), quer-
cetin (100 μM) or kaempferol (100 μM). The increase in absorbance at
412 nm was continuously recorded over 5 min, until a steady value was
reached. The results shown are the average of triplicate experiments.
Fig. 6 Effect of reduced glutathione (GSH) on sarcoplasmic reticulum
(SR) Ca2+-ATPase activity in the presence of oxometalates, at IC50 con-
centrations. The ATPase activity was measured as indicated in the
Materials and methods section. Data are plotted as means ± SD. The
results shown are the average of triplicate experiments.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans.
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induced by external or internal factors. For instance, peptide
tyrosine phosphorylation results in two bands at ca. 825 and
853 cm−1.48–50 The ratio of intensities of these bands gives indi-
cations about the strength of tyrosine hydrogen bonding.48–50 In
the present study, this Fermi resonance doublet was not
observed, but instead only a single band at 837 cm−1 (Fig. 7A)
was found. Such an observation could be interpreted in two
ways: (i) the tyrosine units are not involved in hydrogen
bonding48 or (ii) the tyrosine residues are phosphorylated,
leading to the collapse of the doublet into a single band.48–50
While the ﬁrst hypothesis should be discarded, because the tyro-
sines would have to be facing the interior of the protein instead
of interacting with bulk water, the second one is unlikely
because it is known that the Ca2+-ATPase is phosphorylated in
aspartic acid.30,32
In the present study, we collected spectra on protein confor-
mation E1 – medium containing calcium, or on protein confor-
mation E1P, in the presence of ATP (Fig. 7A). It is suggested
that the more intense peak at 1650 cm−1 corresponds to the
amide I CvO stretching vibration of the peptide, and the peak at
1150 cm−1 probably can be assigned to the CH2 deformation
from lipid hydrocarbon,51,52 once the sample contains not only
the membranar protein but also the native lipid bilayer from the
sarcoplasmic reticulum. The changes in the intensity of the peak
at 1150 cm−1 can be probably due to metal-induced changes to
the CH2 in lipid molecules,
52 that would suggest an effect on the
lipid-membrane structure. An increase in the peak at 1650 cm−1,
ascribed to amide I (CvO stretching vibration of the peptide), is
also observed (Fig. 7A), indicating changes in the secondary
structure of the protein. No signiﬁcant changes were detected,
when the protein is susceptible to phosphorylation by inorganic
phosphate, in a medium containing EGTA that complexes all the
free calcium and inorganic phosphate (not shown). These con-
ditions favour conformation E2 and by extension the E2P con-
formation. Also by comparing the Raman spectra of the calcium
ATPase in both conformations E1 and E2, no signiﬁcant differ-
ences were detected (not shown), in agreement with observations
in similar studies with the Na+, K+, ATPase.52
Both molybdate and tungstate induce distinct changes in the
intensities of the peaks (Fig. 8A and B), suggesting that those
oxometalates are promoting different protein conformation
changes. In comparison with the E1P spectra, upon addition of
Mo, peaks at 837, 1075 and 1465 cm−1 did not change, while
the peak at 1650 cm−1 is more intense and peaks at 926, 1150
and 1380 cm−1 are weaker (Fig. 8A). For W, a decrease in the
bands, relative to E1P, was detected for all the ﬁrst six peaks
found in the spectra whereas the last peak at 1650 cm−1
remained unchanged (Fig. 8B). For Mo, the increases on
α-helices point to a structure-organizing effect, but clearly the
Mo interaction seems to induce different calcium ATPase protein
conformational changes than W, although as described above
they both favour an E1 type conformation. In contrast to the
former oxometalates, upon incubation of the protein with Nb10
or V10, a decrease in the intensities of all the peaks was observed
(Fig. 9). Furthermore, the decrease in the intensities of all the
peaks upon V10 and Nb10 interaction, observed for the E1 con-
formation, was also detected in the Raman spectra of the enzyme
in the E2 conformation, that is, absence of free calcium due to
the presence of EGTA in the medium, suggesting that those oxo-
metalates affect both spectra of the E1 or E2 protein confor-
mation (not shown).
In contrast to the effects induced by V and Nb on the protein
Raman spectra at the E1 or E2 conformation, no signiﬁcant
changes were detected in the Raman spectra upon phosphate or
tungstate addition to the enzyme in the E2 conformation,
whereas a small decrease was observed for molybdate (not
shown). Note that the presence of any natural ligand of the Ca2+-
ATPase will induce major conformational changes in the protein,
thus affecting oxometalate interactions. In addition to the
binding to the cytoplasmic domains, other binding sites for deca-
meric vanadate have been suggested, such as the speciﬁc inter-
molecular binding sites described to be essential to induce
crystal formation.9,10 Therefore, although it has been used to
resolve the structure of enzyme in the E2 state,10 V10 seems to
behave unlike a natural ligand of the enzyme.
Raman spectroscopy can also be used to characterize oxome-
talate solutions,53 the exploration of the viability of this approach
Fig. 9 Raman spectra of calcium ATPase upon addition of decavana-
date (left) or decaniobate (right).
Fig. 7 Raman spectra of calcium ATPase at conformation states E1
upon phosphorylation (E1P).
Fig. 8 Raman spectra of calcium ATPase in the presence of molybdate
(left) or tungstate (right) in the medium. Mo decreases the peak at
1150 cm−1, and it increases the peak at 1650 cm−1, belonging probably
to the CH2 deformations in lipid molecules and the amide I CvO
stretching vibration of the peptide, respectively. For W, a decrease in the
bands, in comparison with E1P, was detected for all the ﬁrst six peaks,
whereas the last peak at 1650 cm−1, shows the same intensity.
Dalton Trans. This journal is © The Royal Society of Chemistry 2012
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to decavanadate and decaniobate solutions is currently underway.
A preliminary study suggests that the more stable Nb10 oxometa-
late is an excellent tool to elucidate V10 chemistry in solution
(Batista de Carvalho et al., unpublished results). Based on the
data, it appears that V10 and Nb10 induce similar Ca
2+-ATPase
conformational changes, which are different from the known
conformers E1 or E2, once similar changes in the Raman spectra
were detected (Fig. 9 and not shown). W and Mo cause yet
another set of conformations. It is suggested that tungstate and
molybdate induce the same type of structural changes that are
seen in inorganic phosphorylation, but that Nb10, vanadate and
V10 cause different changes corresponding to an as of yet
unknown type of structure. These latter oxometalates interact
with both the E1 and E2 states, while this is not the case of the
tungstate and molybdate. It is clear that Raman spectroscopy can
be a useful diagnostic tool in providing additional information
on the effect of oxometalates on calcium ATPase conformation
and as such complements EPR and NMR.
4. Conclusion
In spite of the attention paid to the role of oxometalates in bio-
logical systems in recent years, their potential and modes of
action are still poorly understood. For example, their inﬂuence
on the activity of calcium pump ATPase, a key enzyme in
homeostasis, is yet to be fully understood. Based on the ﬁndings
in this study, it is concluded that V10 shows a speciﬁc interaction
with the calcium pump in comparison to other oxometalates.
It induces cysteine oxidation and undergoes non-competitive
inhibition. The ATPase inhibition is not reverted by GSH or
quercetin, but the cysteine oxidation is partially prevented by
antioxidants such as quercetin. Moreover, V10 does not discrimi-
nate against any of the protein conformations that occur during
the process of calcium translocation, but binds to all of them.
Raman spectroscopy points to speciﬁc calcium ATPase confor-
mational changes being induced by the oxometalates, but that
these changes depend on what oxometalates are present. There-
fore, this work conﬁrms the fact that vanadate interaction with
proteins, not only with actin but also with SR Ca-ATPase, can
impact thiols and undergoing vanadium reduction. It is believed
that the present observations will contribute to the understanding
of oxometalate interactions with the calcium pump and the role
of V10 in biology, particularly the mechanisms of V10 interaction
with ionic pumps.
The isostructural Nb10 is shown to be an excellent tool for
clarifying the mode of interaction and the effects of V10 on the
calcium pump. Raman spectroscopy points to a new approach on
the interaction of oxometalates with the calcium pump, ﬁnding
distinct protein conformational changes, similar to E1P or to
none of the established conformations induced by the presence
of oxometalates. Putting it all together, it is suggested to be due
to the putative reduction of vanadate as well as the non-competi-
tive V10 binding, and would explain why monomeric molybdate
and tungstate behave differently regarding the interaction with
the SR calcium pump. We conclude that it is the V10 or the vana-
date interaction with calcium ATPase which induces cysteine
oxidation and the concomitant vanadate reduction. Therefore,
many aspects of the interactions between the different
oxometalates and the calcium pump are yet to be clariﬁed.
Although some are chemically very similar they induce different
effects on the structure and on the function of the protein.
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